Chemotherapy Dosing Errors: Seeking Justice for Cancer Patients in NY

How Chemotherapy Dosing Errors Happen

Chemotherapy dosing errors occur through several mechanisms:

• Dose calculation errors: Chemotherapy doses are calculated based on the patient's body surface area (BSA) or weight — and sometimes kidney function. Errors in measuring weight, height, or calculating BSA can lead to significant dose errors.
• Wrong drug selection: Administering the wrong chemotherapy agent — particularly drugs with similar names (e.g., vincristine vs. vinblastine, cisplatin vs. carboplatin). [Link to: /medication-errors/wrong-drug-interaction]
• Wrong concentration or dilution: Preparing the chemotherapy at the wrong concentration — or with the wrong diluent — causing an overdose or underdose.
• Wrong infusion rate: Administering the chemotherapy too quickly — some drugs must be infused slowly to prevent toxicity.
• Wrong route of administration: Giving a drug intravenously that should be given intrathecally (into the spinal fluid) — or vice versa. Intrathecal administration of vincristine (which should only be given IV) is a catastrophic, usually fatal error.
• Schedule errors: Administering chemotherapy too frequently — or not allowing adequate recovery time between cycles.
• Failure to adjust for organ function: Many chemotherapy drugs are metabolized by the kidneys or liver. Failure to adjust the dose for impaired kidney or liver function can cause drug accumulation and severe toxicity.
• Failure to adjust for prior treatment: Patients who have received prior chemotherapy may have cumulative toxicity — requiring dose adjustments.
• Pharmacy preparation errors: The pharmacy may prepare the wrong drug, wrong concentration, or wrong volume — and the error reaches the patient.
• Failure to verify: The standard of care requires independent double-check of chemotherapy orders — by a physician, pharmacist, and nurse. Failure to verify can allow errors to reach the patient.
• Miscommunication during handoffs: During shift changes or transfers, critical information about the chemotherapy regimen may be miscommunicated or lost.
• Confusion between similar protocols: Cancer treatment often involves complex, multi-drug protocols — and confusion between protocols can cause errors.

The Standard of Care for Chemotherapy Administration

The standard of care for chemotherapy administration is established by the American Society of Clinical Oncology (ASCO), the Oncology Nursing Society (ONS), and the Joint Commission. Key elements include:

1. Accurate patient assessment: Measuring weight and height accurately, calculating body surface area (BSA), and assessing organ function (kidney, liver, bone marrow) before each cycle.

2. Meticulous dose calculation: Calculating the dose based on BSA, weight, or other patient-specific factors — with attention to maximum dose limits, cumulative dose limits, and prior treatment history.

3. Independent double-check: The standard of care requires an independent double-check of chemotherapy orders — by a physician, pharmacist, and nurse. Each verifies the drug, dose, route, schedule, and patient identity independently.

4. Proper preparation: Chemotherapy should be prepared in a specialized pharmacy (USP 800 compliant) — with proper technique, diluent, concentration, and labeling.

5. Correct administration technique: Using the correct route (IV, intrathecal, oral, etc.), correct infusion rate, and correct sequence for multi-drug protocols.

6. Patient identification: Using two patient identifiers (name and date of birth) before administering chemotherapy.

7. Pre-treatment lab verification: Checking blood counts (CBC), kidney function, and liver function before each cycle — and holding or reducing the dose if labs are abnormal.

8. Monitoring during and after administration: Monitoring for infusion reactions, extravasation, and adverse effects — with immediate intervention if they occur.

When a Chemo Error Constitutes Medical Malpractice

A chemotherapy dosing error constitutes medical malpractice when the healthcare provider failed to meet the standard of care in calculating, preparing, verifying, or administering the chemotherapy. Common breaches include:

• The provider calculated the dose incorrectly — based on wrong weight, height, BSA, or organ function.
• The provider selected the wrong drug — particularly drugs with similar names.
• The pharmacy prepared the wrong drug, concentration, or volume.
• The provider administered the wrong route — particularly the catastrophic error of administering vincristine intrathecally.
• The provider administered the wrong infusion rate — too fast, causing toxicity.
• The provider failed to adjust for organ function — causing drug accumulation and severe toxicity.
• The provider failed to perform an independent double-check — allowing the error to reach the patient.
• The provider failed to check pre-treatment labs — administering chemotherapy despite abnormal blood counts or organ function.
• The provider failed to monitor during and after administration — missing signs of toxicity or extravasation.

Consequences of Chemotherapy Overdoses

When a chemotherapy overdose occurs, the consequences can be devastating — sometimes more dangerous than the cancer itself:

• Severe bone marrow suppression: Overdose destroys the bone marrow — causing severe neutropenia (low white blood cells, leading to life-threatening infections), thrombocytopenia (low platelets, leading to bleeding), and anemia (low red blood cells). May require prolonged hospitalization, IV antibiotics, blood transfusions, and growth factor support.
• Severe infections: From neutropenia — the patient's immune system is destroyed, making them vulnerable to bacterial, fungal, and viral infections. Sepsis and death can occur. [Link to: /medical-malpractice/sepsis-malpractice]
• Severe bleeding: From thrombocytopenia — internal bleeding, brain hemorrhage, and death.
• Organ damage: Kidney failure (particularly from cisplatin and methotrexate), liver damage, heart damage (from anthracyclines like doxorubicin), lung damage (from bleomycin), and neurological damage (from vincristine and taxanes).
• Permanent organ failure: Requiring dialysis (kidney failure), heart transplant (heart failure), or other interventions.
• Secondary cancers: Chemotherapy itself can cause cancer — and an overdose increases the risk of developing secondary cancers (leukemia, lymphoma) in the future.
• Death: Chemotherapy overdoses can be fatal — particularly from overwhelming infection, bleeding, or organ failure.
• Reduced quality of life: Severe and prolonged side effects, extended hospitalization, loss of independence, and psychological trauma.
• Delayed or compromised cancer treatment: After an overdose, the patient's cancer treatment may need to be delayed or modified — potentially allowing the cancer to progress.

The 'Loss of Chance' Doctrine in Chemo Error Cases

The Loss of Chance doctrine is particularly important in chemotherapy error cases. When a chemo overdose causes additional harm — or compromises the patient's cancer treatment — the Loss of Chance doctrine allows recovery for the reduced probability of survival or better outcome.

Example: A patient has Stage 2 breast cancer with a 75% 5-year survival rate with standard chemotherapy. A dosing error causes severe bone marrow suppression, delaying the next cycle of chemotherapy — allowing the cancer to progress to Stage 3, with a 55% survival rate. The Loss of Chance doctrine allows the patient to recover damages for the 20 percentage points of lost survival probability.

New York allows full recovery of damages when the error was a "substantial factor" in reducing the patient's chances. [Link to: /misdiagnosis/loss-of-chance]

Proving Causation in Chemotherapy Cases

Proving that a chemotherapy error caused the patient's harm requires establishing:

1. The standard of care was breached: Expert testimony that the provider miscalculated the dose, selected the wrong drug, failed to verify, or failed to monitor.

2. The error caused the harm: Expert testimony linking the dosing error to the specific harm — bone marrow suppression, organ damage, infection, or death — based on medication records, lab values, and the clinical course.

3. A correct dose would have prevented the harm: Expert testimony that if the dose had been correct, the bone marrow suppression, organ damage, or death would not have occurred.

4. The Loss of Chance doctrine applies: Expert testimony about how the error reduced the patient's probability of survival or better outcome — supporting recovery for the reduced chance.

The defense may argue that chemotherapy always carries risks, that the patient's underlying cancer contributed to the outcome, or that the harm was an expected side effect. Expert testimony is required to counter these arguments — distinguishing expected side effects from negligent overdoses.

Who Is Liable for a Chemo Error?

Multiple parties may be liable for a chemotherapy error, depending on where the error occurred:

• The prescribing oncologist: Who calculated the dose, selected the drug, or failed to adjust for organ function.
• The oncology pharmacist: Who prepared the wrong drug, concentration, or volume — or failed to verify the order.
• The oncology nurse: Who administered the wrong drug, wrong rate, or wrong route — or failed to verify the order.
• The hospital or cancer center: Under vicarious liability for its employees — and direct liability for inadequate protocols, staffing, or safety systems.
• The pharmacy: If a separate pharmacy prepared the chemotherapy.
• The electronic health record (EHR) vendor: In some cases — if a software bug or design flaw contributed to the error.

New York Statute of Limitations

Under CPLR § 214-a, the statute of limitations is 2.5 years from the date of the chemo error. Lavern's Law may apply — because these cases involve cancer — providing a discovery rule: 2.5 years from discovery, with a 7-year outer limit. The continuous treatment doctrine may also extend the deadline — particularly relevant in cancer cases where patients see the same oncologist for years. For wrongful death, the deadline is 2 years from the date of death. [Link to: /misdiagnosis/laverns-law] [Link to: /medication-errors/statute-of-limitations]

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.